Literature DB >> 8641121

Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial.

E Chantelau1, T Tanudjaja, F Altenhöfer, Z Ersanli, S Lacigova, C Metzger.   

Abstract

To investigate the effect of oral antibiotics in purely neuropathic ulcers (Wagner grade 1-2, no osteomyelitis), a double blind placebo-controlled study was performed. Forty-four patients were enrolled and subjected to standard treatment with absolute pressure relief (half shoes), daily wound cleansing (topical disinfectant), sterile dressings (specialized nurse). Patients were randomized to an antibiotic (amoxicillin plus clavulanic acid), or placebo. The study was stopped when the antibiotic proved unsuitable according to swab result, or on clinical grounds (no improvement within 6 days of recruitment). Main outcome measure was the ulcer closing rate during 20 days, as assessed by standardized photographs. All ulcers except one were infected. Of the placebo group (n = 22), 2 patients had to be withdrawn within 6 days, versus 3 patients of the antibiotic-group (n = 22). In the placebo group, 10 ulcers were healed versus 6 ulcers in the antibiotic group (NS). Mean (95% CI) reduction in ulcer radius was 0.41 (0.21-0.61) mm day-1 in the placebo group versus 0.27 (0.15-0.39) mm day-1 in the antibiotic group (NS). In conclusion, there is no benefit from antibiotic treatment with amoxicillin plus clavulanic acid as a supplement to standard therapy in uncomplicated neuropathic foot ulcers, provided pressure relief is complete, and wound care is performed strictly supervised. However, a Type-II statistical error cannot be excluded in this small study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641121     DOI: 10.1002/(SICI)1096-9136(199602)13:2<156::AID-DIA59>3.0.CO;2-U

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  9 in total

1.  A Current Approach to Diabetic Foot Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

2.  Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers.

Authors:  A Sotto; J-L Richard; C Combescure; N Jourdan; S Schuldiner; N Bouziges; J-P Lavigne
Journal:  Diabetologia       Date:  2010-06-23       Impact factor: 10.122

Review 3.  Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication.

Authors:  Malcolm Gillies; Anggi Ranakusuma; Tammy Hoffmann; Sarah Thorning; Treasure McGuire; Paul Glasziou; Christopher Del Mar
Journal:  CMAJ       Date:  2014-11-17       Impact factor: 8.262

4.  New insights in diabetic foot infection.

Authors:  Jean-Louis Richard; Albert Sotto; Jean-Philippe Lavigne
Journal:  World J Diabetes       Date:  2011-02-15

5.  Diabetic foot ulcers: practical treatment recommendations.

Authors:  Michael Edmonds
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Optimising antimicrobial therapy in diabetic foot infections.

Authors:  Nalini Rao; Benjamin A Lipsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Infections in Diabetic Foot Ulcerations.

Authors:  Warren S. Joseph; James S. Tan
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

8.  Virulence and Drug-Resistance of Staphylococcus aureus Strains Isolated from Venous Ulcers in Polish Patients.

Authors:  Mateusz Gajda; Emilia Załugowicz; Monika Pomorska-Wesołowska; Tomasz Bochenek; Barbara Gryglewska; Dorota Romaniszyn; Agnieszka Chmielarczyk; Jadwiga Wójkowska-Mach
Journal:  Int J Environ Res Public Health       Date:  2021-04-27       Impact factor: 3.390

9.  Can We Stop Antibiotic Therapy When Signs and Symptoms Have Resolved in Diabetic Foot Infection Patients?

Authors:  Yuejie Chu; Chao Wang; Jinghang Zhang; Penghua Wang; Jun Xu; Min Ding; Xiwen Li; Xiaoli Hou; Shuhong Feng; Xuemei Li
Journal:  Int J Low Extrem Wounds       Date:  2015-08-06       Impact factor: 2.057

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.